Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01240330 · ClinicalTrials.gov registry record · NA

Vasculaire Compression System Increases Flow Velocity in the Femoral Vein

A NA study of Venous Thrombosis, sponsored by Venous Health Systems.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT01240330: Completed NA study of Venous Thrombosis, sponsored by Venous Health Systems.

NCT01240330 is a NA study of Venous Thrombosis that has completed, run by Venous Health Systems. The registered enrollment target is 33 participants, below the 1,121-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01240330, a NA study of Venous Thrombosis, has completed, sponsored by Venous Health Systems.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The objective of this clinical study was to demonstrate the performance of the Vasculaire Compression System to increase femoral venous peak velocity (PFV) in healthy subjects. This study was a single-arm, open label, prospective, single-center clinical study.

Primary Outcome

The femoral vein in the mid-thigh area was located and the femoral venous Peak Flow Velocity (PFV)was measured using duplex ultrasound during the compression phase of treatment. PFV is the maximum velocity of blood flow achieved when the foot and calf compression is applied. The PFV was then compared to the subject's own baseline PFV using a paired t-test.

Conditions Studied

Interventions

  • DEVICE Pneumatic Compression therapy

Study Locations (1)

California

  • Venous Health System, Inc. - Portola Valley

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2010-08
Est. Completion 2010-09
Phase NA
Venous Health Systems

1 total trials

What the finished NCT01240330 record still lists

NCT01240330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,121-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Venous Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Pneumatic Compression therapy is the first listed.

NCT01240330 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01240330 about?

NCT01240330 is a clinical study titled "Vasculaire Compression System Increases Flow Velocity in the Femoral Vein". The objective of this clinical study was to demonstrate the performance of the Vasculaire Compression System to increase femoral venous peak velocity (PFV) in healthy subjects. This study was a single-arm, open label, prospective, single-center clinical study.

What is the current status of trial NCT01240330?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2010-08. Estimated completion is 2010-09.

What conditions does trial NCT01240330 study?

This clinical trial studies the following conditions: Venous Thrombosis.

What interventions are being tested in trial NCT01240330?

The interventions under investigation include: Pneumatic Compression therapy (DEVICE).

Who is sponsoring clinical trial NCT01240330?

This trial is sponsored by Venous Health Systems, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01240330 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Thrombosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01240330's enrollment target sits among peer trials

33 8th of 9 higher than 2 of 9 other Venous Thrombosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01240330, the US trial registry maintained by the National Library of Medicine. NCT01240330 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.